Helix, the Silicon Valley company that’s styled itself as an app store for DNA tests, made a splash last week when it announced it had raised $200 million — the latest windfall for a company leveraging a boom in consumer genomics.
But as money sloshes around the industry, there’s an uneasy and unsettled question gnawing at even the most bullish investors: Are these bets going to pay off?
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Great reporting and a cool animated DNA/money graphic. You can look at it two ways: 1) money is “poring” into DTC genomics, or 2) investments are going down the well.